Targeted cancer treatments may reduce morbidities and extend patient survival. Cellectar’s cutting-edge PDCs are at the forefront of targeted cancer treatments.
Our PDC platform takes advantage of a metabolic shift utilized by all tumor cell types in all stages of the tumor cycle. This means that our PDCs can target and gain intracellular access to most primary tumors, metastatic sites, and cancer stem cells. This approach may enhance drug efficacy and simultaneously minimize side effects for patients.
Our proprietary PLE delivery platform was engineered to be conjugated (combined) with a wide variety of therapeutic molecules, such as small-molecule chemotherapeutics, radiotherapeutics, and other molecules that utilize alternative therapeutic approaches. In some cases, linkers are specifically designed to securely attach the therapeutic molecule to the PLE. Once inside the tumor cell, the linker is cleaved, and the molecules are released killing the tumor cell.